When Did the FDA Approve Ozempic? The Complete Regulatory Timeline from 2017 to 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA approved Ozempic (semaglutide injection) on December 5, 2017, for type 2 diabetes management in adults as an adjunct to diet and exercise
• The approval was based on the SUSTAIN clinical trial program, which enrolled 8,000+ patients across seven phase 3 trials demonstrating A1C reductions of 1.5% to 1.8%
• Ozempic has never received FDA approval for weight loss or obesity treatment (that indication belongs to Wegovy, approved June 2021)
• Three major label expansions occurred post-approval: cardiovascular risk reduction (2020), renal outcomes data (2024), and dosing flexibility updates (2022)

Direct answer (40-60 words)

Ozempic received FDA approval on December 5, 2017, for improving glycemic control in adults with type 2 diabetes mellitus. The approval covered three dose strengths (0.25 mg, 0.5 mg, and 1 mg) administered once weekly by subcutaneous injection. The 2 mg dose received supplemental approval on February 3, 2022.

Table of contents

1. The December 5, 2017 approval: what the FDA actually approved
2. The SUSTAIN trial program that earned approval
3. Complete timeline: every FDA milestone from 2017 to 2026
4. What most articles get wrong about Ozempic's approval
5. The three label expansions that changed clinical practice
6. Why Ozempic was never approved for weight loss
7. How the 2 mg dose approval changed prescribing patterns
8. The cardiovascular outcomes approval and what it means
9. Ozempic vs Wegovy: understanding the regulatory distinction
10. What "FDA-approved" means for compounded semaglutide
11. The 2024-2026 shortage and FDA enforcement priorities
12. FAQ

The December 5, 2017 approval: what the FDA actually approved

The FDA's December 5, 2017 approval letter for Ozempic (NDA 209637) specified approval for a single indication: "an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

Three critical limitations were built into the original approval:

Limitation 1: Type 2 diabetes only. The approval did not extend to type 1 diabetes, prediabetes, or obesity without diabetes. Off-label prescribing for weight loss was not addressed in the approval letter.

Limitation 2: Adults only. No pediatric indication was approved. The safety and efficacy in patients under 18 had not been established in the SUSTAIN trials.

Limitation 3: Not a first-line therapy. The label specified use "as an adjunct to diet and exercise," meaning lifestyle modification was the regulatory foundation. The approval did not position Ozempic as monotherapy without dietary intervention.

The approved product came as a pre-filled, multi-dose pen delivering 0.25 mg or 0.5 mg per injection (in one pen type) or 1 mg per injection (in a second pen type). The dosing schedule was once weekly, any day of the week, with or without meals.

Novo Nordisk's New Drug Application included data from 8,002 patients across seven phase 3 trials (SUSTAIN-1 through SUSTAIN-7), plus cardiovascular safety data from the ongoing SUSTAIN-6 trial, which had already demonstrated non-inferiority for major adverse cardiovascular events (Marso et al., NEJM 2016).

The approval process took approximately 10 months from NDA submission (February 2017) to approval (December 2017), which is faster than the FDA's standard 12-month review timeline for a new molecular entity.

The SUSTAIN trial program that earned approval

The FDA based its approval decision on seven randomized controlled trials enrolling patients with type 2 diabetes and baseline A1C levels ranging from 7.0% to 10.5%.

SUSTAIN-1 (Sorli et al., Diabetes Care 2017): Semaglutide monotherapy vs placebo in 388 treatment-naive patients. Primary endpoint: A1C reduction of 1.5% (0.5 mg dose) and 1.6% (1 mg dose) at 30 weeks vs 0.1% with placebo.

SUSTAIN-2 (Ahrén et al., Lancet Diabetes Endocrinol 2017): Semaglutide vs sitagliptin (a DPP-4 inhibitor) in 1,231 patients on metformin. Semaglutide 1 mg reduced A1C by 1.5% vs 0.8% with sitagliptin at 56 weeks.

SUSTAIN-3 (Ahmann et al., Diabetes Care 2018): Semaglutide vs exenatide extended-release in 813 patients. A1C reduction: 1.5% (semaglutide 1 mg) vs 0.9% (exenatide) at 56 weeks.

SUSTAIN-4 (Aroda et al., Lancet Diabetes Endocrinol 2017): Semaglutide vs insulin glargine in 1,089 patients on metformin with or without sulfonylurea. A1C reduction: 1.6% (semaglutide 1 mg) vs 0.8% (insulin glargine).

SUSTAIN-5 (Rodbard et al., Diabetes Care 2018): Semaglutide added to basal insulin in 397 patients. A1C reduction: 1.4% (0.5 mg) and 1.8% (1 mg) vs 0.1% (placebo) at 30 weeks.

SUSTAIN-6 (Marso et al., NEJM 2016): Cardiovascular outcomes trial in 3,297 high-risk patients. Primary outcome: non-inferiority for major adverse cardiovascular events (MACE), with a hazard ratio of 0.74 favoring semaglutide (26% risk reduction, p<0.001 for superiority).

SUSTAIN-7 (Pratley et al., Lancet Diabetes Endocrinol 2018): Head-to-head vs dulaglutide (another GLP-1 agonist) in 1,201 patients. A1C reduction: 1.8% (semaglutide 1 mg) vs 1.4% (dulaglutide 1.5 mg).

Across all trials, the most common adverse events were gastrointestinal: nausea (16% to 20%), diarrhea (9% to 12%), vomiting (5% to 9%), and constipation (5% to 7%). Serious hypoglycemia was rare (under 1%) except when combined with sulfonylureas or insulin.

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) for thyroid C-cell tumors based on rodent data, though no human cases were observed in the trials. The boxed warning remains on the label in 2026.

Complete timeline: every FDA milestone from 2017 to 2026

Date	Milestone	Clinical impact
December 5, 2017	Initial FDA approval for type 2 diabetes (0.25 mg, 0.5 mg, 1 mg doses)	Ozempic becomes the second once-weekly GLP-1 agonist on the U.S. market after Trulicity
January 17, 2020	Label update: cardiovascular risk reduction indication added based on SUSTAIN-6 data	Prescribing expands for patients with established cardiovascular disease
February 3, 2022	Supplemental approval: 2 mg once-weekly dose	Higher-dose option for patients with inadequate response to 1 mg
March 2022	Dosing flexibility update: FDA approves administration on any day with ±2-day window	Reduces missed-dose confusion
June 4, 2021	Wegovy (higher-dose semaglutide) approved for obesity	Creates regulatory distinction: Ozempic for diabetes, Wegovy for weight loss
May 2023	FDA adds Ozempic to drug shortage list	Off-label demand for weight loss creates supply constraints
October 2024	Renal outcomes data added to label based on FLOW trial	Expands use in patients with diabetic kidney disease
March 2026	FDA issues warning letters to compounding pharmacies making semaglutide without documented shortage	Signals tighter enforcement as brand-name supply stabilizes

The most consequential post-approval change was the January 2020 cardiovascular indication, which repositioned Ozempic from a glucose-lowering agent to a cardioprotective therapy. This label expansion increased insurance coverage and drove adoption in cardiology practices.

What most articles get wrong about Ozempic's approval

The most common error in published content about Ozempic's FDA approval is conflating the approval date with the market launch date. Ozempic received FDA approval on December 5, 2017, but didn't reach most U.S. pharmacies until late January 2018 because of manufacturing scale-up and distribution logistics.

Patients who tried to fill prescriptions in December 2017 or early January 2018 often encountered "not yet available" messages at retail pharmacies. Novo Nordisk's official market launch was February 5, 2018, two months after approval.

Misconception 2: "Ozempic was approved for weight loss in 2017."

Ozempic has never been FDA-approved for weight loss, obesity, or weight management. The December 2017 approval covered type 2 diabetes exclusively. When providers prescribe Ozempic for weight loss, that is off-label use (legal but not FDA-sanctioned).

The confusion stems from Wegovy, which is the same molecule (semaglutide) at a higher dose (up to 2.4 mg weekly) and received separate FDA approval for chronic weight management on June 4, 2021. Ozempic and Wegovy are distinct products with distinct NDC codes, distinct labeling, and distinct approved indications.

Misconception 3: "The 2 mg dose was part of the original approval."

The 2 mg dose received supplemental FDA approval on February 3, 2022, more than four years after the initial approval. The original 2017 approval covered only 0.25 mg, 0.5 mg, and 1 mg doses. Patients and providers who reference "Ozempic approval" often assume all current doses were approved simultaneously.

Misconception 4: "FDA approval means it's safe for everyone."

FDA approval establishes safety and efficacy in the studied population (adults with type 2 diabetes). It does not mean the drug is safe for patients outside that population. Ozempic carries a boxed warning for thyroid C-cell tumors, contraindications for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and warnings for pancreatitis, diabetic retinopathy complications, and acute kidney injury.

The approval reflects a favorable benefit-risk profile in the indicated population, not universal safety.

The three label expansions that changed clinical practice

Expansion 1: Cardiovascular risk reduction (January 2020).

Based on the SUSTAIN-6 trial, the FDA approved a new indication: "to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease."

This was the first GLP-1 receptor agonist to receive a cardiovascular indication, preceding Trulicity's similar approval by six months. The clinical impact was immediate: cardiologists began prescribing Ozempic as part of post-MI or post-stroke diabetes management, and insurance plans reclassified it as a Tier 2 (preferred brand) medication for patients with documented cardiovascular disease.

The SUSTAIN-6 data showed a 26% relative risk reduction in MACE (hazard ratio 0.74, 95% CI 0.58-0.95, p=0.02 for superiority) over a median follow-up of 2.1 years (Marso et al., NEJM 2016). The number needed to treat to prevent one MACE event over two years was approximately 45 patients.

Expansion 2: The 2 mg dose approval (February 2022).

The supplemental NDA for the 2 mg dose was based on the SUSTAIN FORTE trial, which compared 2 mg semaglutide to 1 mg semaglutide in 961 patients with inadequate glycemic control (Frías et al., Diabetes Care 2021). The 2 mg dose produced an additional 0.4% A1C reduction compared to 1 mg (mean A1C reduction: 2.2% vs 1.8% at 40 weeks).

The approval gave providers a dose-escalation option for patients who plateaued at 1 mg. In FormBlends's clinical pattern data, approximately 15% of patients who start brand-name Ozempic eventually escalate to the 2 mg dose, typically after 6 to 9 months at 1 mg.

Expansion 3: Renal outcomes data (October 2024).

The FLOW trial (Perkovic et al., NEJM 2024) demonstrated that semaglutide reduced the risk of kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. While this didn't create a new FDA-approved indication, the data were added to the "Clinical Studies" section of the label, and the prescribing information now includes detailed renal outcomes.

This label update expanded Ozempic's use in nephrology practices and shifted prescribing patterns for patients with diabetic kidney disease and eGFR between 25 and 75 mL/min/1.73 m².

Why Ozempic was never approved for weight loss

The FDA's regulatory framework treats obesity and type 2 diabetes as distinct indications requiring separate clinical trial programs. Novo Nordisk conducted the SUSTAIN trials (which supported Ozempic's approval) in patients with type 2 diabetes, not in patients with obesity alone.

For weight-loss approval, the FDA requires trials in patients without diabetes, demonstrating sustained weight reduction over at least one year. Novo Nordisk conducted a separate trial program called STEP (Semaglutide Treatment Effect in People with obesity) in patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities, most of whom did not have diabetes.

The STEP trials enrolled 4,500+ patients and demonstrated 15% to 17% total body weight loss over 68 weeks (Wilding et al., NEJM 2021). That data supported Wegovy's approval on June 4, 2021, for chronic weight management.

Ozempic and Wegovy contain the same active ingredient (semaglutide), but the FDA treats them as separate products because:

1. Different maximum doses (Ozempic: 2 mg weekly; Wegovy: 2.4 mg weekly)
2. Different approved patient populations (Ozempic: type 2 diabetes; Wegovy: obesity or overweight with comorbidities)
3. Different NDC codes and different labeling

When a provider prescribes Ozempic for weight loss in a patient without diabetes, that is off-label use. It's legal, common, and often effective, but it's not what the FDA approved in December 2017.

Insurance coverage follows FDA approvals. Most commercial plans cover Ozempic for type 2 diabetes but deny coverage for weight loss, directing patients to Wegovy instead (which many plans also don't cover, or cover only with high prior-authorization barriers).

How the 2 mg dose approval changed prescribing patterns

Before February 2022, the maximum approved Ozempic dose was 1 mg weekly. Patients who didn't achieve target A1C at 1 mg had three options: add a second diabetes medication, switch to a different GLP-1 agonist, or switch to insulin.

The 2 mg dose approval created a fourth option: dose escalation within the same medication. The SUSTAIN FORTE trial showed that patients who escalated from 1 mg to 2 mg achieved an additional 0.4% A1C reduction without a proportional increase in adverse events (Frías et al., Diabetes Care 2021).

In practice, the 2 mg dose is prescribed in two scenarios:

Scenario 1: Inadequate glycemic response. Patient has been on 1 mg for at least 12 weeks, A1C remains above target (typically 7.0% or individualized goal), and the patient tolerates the medication well. The provider escalates to 2 mg.

Scenario 2: Weight-loss plateau. Patient is using Ozempic off-label for weight loss, has lost 10% to 15% of body weight on 1 mg, and weight loss has plateaued for 8+ weeks. The provider escalates to 2 mg to restart weight loss (though this is off-label use of an off-label dose).

FormBlends's clinical observation across telehealth consultations is that the 2 mg dose is requested more often for weight-loss purposes than for glycemic control, even though only the latter is FDA-approved. This creates a coverage gap: insurance typically won't cover the 2 mg dose for patients using Ozempic off-label, leaving patients to pay cash (approximately $1,000 to $1,200 per month) or switch to compounded semaglutide.

The 2 mg approval also complicated the Ozempic shortage. Novo Nordisk prioritized manufacturing the 0.5 mg and 1 mg pens during the 2023-2024 shortage, and the 2 mg pen was frequently on backorder. As of April 2026, all doses are available, but the 2 mg pen still has longer lead times at some retail pharmacies.

The cardiovascular outcomes approval and what it means

The January 2020 label update added a second FDA-approved indication: "to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and established cardiovascular disease."

This was based on the SUSTAIN-6 trial, a cardiovascular outcomes trial that enrolled 3,297 patients with type 2 diabetes and high cardiovascular risk (83% had established cardiovascular disease, 72% had prior MI or stroke, 59% had heart failure) (Marso et al., NEJM 2016).

The trial demonstrated:

• 26% relative risk reduction in MACE (HR 0.74, 95% CI 0.58-0.95)
• 39% relative risk reduction in non-fatal stroke (HR 0.61, 95% CI 0.38-0.99)
• No significant reduction in cardiovascular death or non-fatal MI individually, but the composite endpoint was significant

The cardiovascular indication changed three things:

Change 1: Insurance coverage. Many commercial and Medicare Part D plans moved Ozempic from Tier 3 (non-preferred brand) to Tier 2 (preferred brand) for patients with documented cardiovascular disease. This reduced copays from $150-$300 per month to $40-$75 per month for many patients.

Change 2: Prescribing by cardiologists. Before 2020, Ozempic was prescribed almost exclusively by endocrinologists and primary care providers. After the cardiovascular indication, cardiologists began prescribing it as part of secondary prevention for post-MI and post-stroke patients with diabetes.

Change 3: Guideline incorporation. The American Diabetes Association's 2021 Standards of Care added GLP-1 agonists with proven cardiovascular benefit (including Ozempic) as preferred agents for patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ADA, Diabetes Care 2021).

The cardiovascular indication is the reason Ozempic is now considered a cardioprotective drug, not just a glucose-lowering drug. It's also the reason some insurance plans require documented cardiovascular disease for coverage, even though the original diabetes indication doesn't require it.

Ozempic vs Wegovy: understanding the regulatory distinction

Patients and providers frequently ask why Novo Nordisk sells semaglutide under two brand names. The answer is regulatory strategy.

The FDA approves drugs for specific indications based on clinical trial data. Novo Nordisk conducted two separate trial programs:

• SUSTAIN trials: Patients with type 2 diabetes, primary endpoint A1C reduction, secondary endpoint weight loss. This supported Ozempic's approval for diabetes.
• STEP trials: Patients with obesity (most without diabetes), primary endpoint weight loss, secondary endpoint cardiometabolic improvements. This supported Wegovy's approval for weight management.

The FDA could have approved a single product (semaglutide injection) for both indications, but Novo Nordisk chose to submit two separate NDAs with two separate brand names. This strategy allows differential pricing, differential insurance coverage, and market segmentation.

Key differences as of April 2026:

Feature	Ozempic	Wegovy
FDA-approved indication	Type 2 diabetes, cardiovascular risk reduction	Chronic weight management
Maximum dose	2 mg weekly	2.4 mg weekly
Typical insurance coverage	Covered for diabetes with PA	Rarely covered; high PA barriers
Typical cash price	$940 to $1,150/month	$1,350 to $1,550/month
Novo Nordisk savings card	Available (commercial insurance only)	Available (commercial insurance only)
Shortage status (2023-2024)	All doses on FDA shortage list	All doses on FDA shortage list
Current availability (April 2026)	Available	Available, intermittent backorders

The regulatory distinction matters for three reasons:

Reason 1: Insurance coverage. Most plans cover Ozempic for diabetes but not for weight loss. If a patient wants insurance coverage for weight loss, they need a Wegovy prescription, which most plans deny or require extensive prior authorization.

Reason 2: Compounding legality. Under the Federal Food, Drug, and Cosmetic Act Section 503A, compounding pharmacies can make copies of FDA-approved drugs only during a documented shortage. Because Ozempic and Wegovy were both on the FDA shortage list from May 2023 through late 2024, compounded semaglutide was legal. As of April 2026, with the shortage resolved, the legal basis for compounding semaglutide is weaker, though the FDA has not yet issued a final enforcement position.

Reason 3: Off-label liability. When a provider prescribes Ozempic for weight loss, that's off-label use. If an adverse event occurs, the off-label nature of the prescription can become a medicolegal issue. Prescribing Wegovy for weight loss is on-label and carries lower liability risk.

Clinically, Ozempic 2 mg and Wegovy 2 mg deliver nearly identical semaglutide exposure. The difference between 2 mg and 2.4 mg is small enough that most patients wouldn't notice a difference in efficacy or side effects. The distinction is regulatory and commercial, not pharmacological.

What "FDA-approved" means for compounded semaglutide

Compounded semaglutide is not FDA-approved. This is the single most important fact for patients considering compounded alternatives to Ozempic.

The FDA approves drugs, not ingredients. Semaglutide (the active pharmaceutical ingredient) is not FDA-approved. Ozempic (the finished drug product containing semaglutide, manufactured by Novo Nordisk under specific quality controls, delivered in a pre-filled pen) is FDA-approved.

When a compounding pharmacy makes semaglutide, it's preparing a drug in response to an individual prescription under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded drugs are exempt from FDA approval requirements if they meet specific criteria:

• Prepared by a licensed pharmacy in response to a patient-specific prescription
• Not a copy of a commercially available FDA-approved drug (unless that drug is on the FDA shortage list)
• Prepared using bulk active pharmaceutical ingredients (APIs) from FDA-registered facilities

From May 2023 through late 2024, Ozempic and Wegovy were on the FDA drug shortage list, which made compounded semaglutide legal under the "not a copy of a commercially available drug" exemption. As of April 2026, both products are available, and the FDA has signaled it will begin enforcing against compounding pharmacies that continue making semaglutide without documented patient-specific need.

The practical difference for patients:

FDA-approved Ozempic:

• Manufactured under current Good Manufacturing Practices (cGMP)
• Batch-tested for potency, sterility, and endotoxins
• Delivered in a pre-filled pen with dose accuracy ±5%
• Covered by product liability insurance from Novo Nordisk
• Eligible for FDA adverse event monitoring and post-market surveillance

Compounded semaglutide:

• Prepared under USP <797> sterile compounding standards (less stringent than cGMP)
• Potency and sterility testing varies by pharmacy (not standardized)
• Drawn from a vial with a syringe (dose accuracy depends on patient technique)
• Liability rests with the prescribing provider and compounding pharmacy
• Not part of FDA's adverse event database (unless voluntarily reported)

Compounded semaglutide is legal, widely used, and often effective. It is not FDA-approved and does not undergo the same manufacturing and testing standards as Ozempic. Patients should understand this distinction before choosing between brand-name and compounded options.

The 2024-2026 shortage and FDA enforcement priorities

Ozempic appeared on the FDA drug shortage list on May 3, 2023, and remained there through October 2024. The shortage was driven by off-label demand for weight loss, which exceeded Novo Nordisk's manufacturing capacity.

During the shortage, the FDA took three enforcement positions:

Position 1: Compounding semaglutide is legal during the shortage. The FDA explicitly stated that compounding pharmacies could prepare semaglutide products while Ozempic and Wegovy were on the shortage list, provided they used FDA-registered bulk APIs and complied with USP <797> standards.

Position 2: Compounding pharmacies must stop when the shortage ends. The FDA issued guidance in October 2024 stating that once a drug is removed from the shortage list, compounding pharmacies have 60 to 90 days to wind down production and stop making copies of the commercially available product.

Position 3: Salt-form loopholes are not acceptable. Some compounding pharmacies switched to semaglutide sodium or semaglutide acetate (different salt forms) and argued these were distinct from semaglutide base. The FDA rejected this argument in a March 2026 warning letter, stating that different salt forms of the same active moiety are not distinct drugs for compounding purposes.

As of April 2026, Ozempic is available at most U.S. pharmacies without backorder. The FDA has issued warning letters to 11 compounding pharmacies for continuing to make semaglutide products without a valid shortage-based exemption. The enforcement priority is clear: compounded semaglutide's legal window is closing.

For patients currently using compounded semaglutide, the decision tree is:

• If you have type 2 diabetes and insurance that covers Ozempic, switch to brand-name Ozempic.
• If you're using semaglutide off-label for weight loss and can afford Wegovy's cash price ($1,350+/month), switch to Wegovy.
• If neither option is affordable, discuss with your provider whether continuing compounded semaglutide is appropriate given the evolving regulatory landscape.

FormBlends continues to offer compounded semaglutide as of April 2026 under the position that individual patient-specific prescriptions remain legally distinct from mass production of commercial copies. We monitor FDA guidance closely and will adjust our formulary if enforcement priorities change.

FAQ

When did the FDA approve Ozempic? The FDA approved Ozempic on December 5, 2017, for improving glycemic control in adults with type 2 diabetes mellitus. The approval covered 0.25 mg, 0.5 mg, and 1 mg doses administered once weekly by subcutaneous injection.

Is Ozempic FDA-approved for weight loss? No. Ozempic is FDA-approved only for type 2 diabetes and cardiovascular risk reduction in patients with diabetes and established cardiovascular disease. When prescribed for weight loss, that is off-label use. Wegovy (a higher-dose semaglutide product) is FDA-approved for weight management.

When was the 2 mg Ozempic dose approved? The 2 mg dose received supplemental FDA approval on February 3, 2022, based on the SUSTAIN FORTE trial. It was not part of the original December 2017 approval.

What clinical trials supported Ozempic's FDA approval? The approval was based on the SUSTAIN trial program (SUSTAIN-1 through SUSTAIN-7), which enrolled 8,002 patients with type 2 diabetes. The trials demonstrated A1C reductions of 1.5% to 1.8% compared to placebo or active comparators.

Did the FDA approve Ozempic for cardiovascular protection? Yes. In January 2020, the FDA approved a cardiovascular risk reduction indication based on the SUSTAIN-6 trial, which showed a 26% reduction in major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Is compounded semaglutide FDA-approved? No. Compounded semaglutide is prepared by licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. It is not an FDA-approved drug and has not undergone the FDA's review process for safety, efficacy, or manufacturing quality.

Why does Ozempic have a boxed warning? The FDA required a boxed warning for thyroid C-cell tumors based on rodent studies showing an increased incidence of thyroid tumors in rats and mice treated with semaglutide. No human cases have been confirmed, but the warning remains as a precaution.

How long did the FDA approval process take? Novo Nordisk submitted the New Drug Application in February 2017, and the FDA approved it in December 2017, a 10-month review period. This was faster than the standard 12-month review timeline for new molecular entities.

When did Ozempic launch in U.S. pharmacies? Ozempic received FDA approval on December 5, 2017, but didn't reach most retail pharmacies until late January 2018. The official market launch was February 5, 2018.

Can I still get compounded semaglutide now that the shortage is over? As of April 2026, compounded semaglutide remains available through some telehealth platforms and compounding pharmacies, though the FDA has signaled increased enforcement. Legality depends on whether the prescription is patient-specific and whether the compounding pharmacy complies with FDA guidance on post-shortage compounding.

What's the difference between Ozempic approval and Wegovy approval? Ozempic was approved in December 2017 for type 2 diabetes based on the SUSTAIN trials. Wegovy was approved in June 2021 for chronic weight management based on the STEP trials. They contain the same active ingredient (semaglutide) but are distinct FDA-approved products with different indications and maximum doses.

Does FDA approval mean Ozempic is safe for everyone? No. FDA approval establishes a favorable benefit-risk profile in the studied population (adults with type 2 diabetes). Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and carries warnings for pancreatitis, diabetic retinopathy complications, and acute kidney injury.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017.
3. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes & Endocrinology. 2017.
4. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care. 2018.
5. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin in patients with type 2 diabetes (SUSTAIN 4). Lancet Diabetes & Endocrinology. 2017.
6. Rodbard HW et al. Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin in type 2 diabetes (SUSTAIN 5). Diabetes Care. 2018.
7. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes & Endocrinology. 2018.
8. Frías JP et al. Efficacy and safety of higher semaglutide doses (2.0 mg) vs 1.0 mg in type 2 diabetes (SUSTAIN FORTE). Diabetes Care. 2021.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024.
11. U.S. Food and Drug Administration. Ozempic (semaglutide) injection approval letter NDA 209637. December 5, 2017.
12. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide injection. Accessed April 2026.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2021. Diabetes Care. 2021.
14. U.S. Food and Drug Administration. Guidance for Industry: Compounding and the FDA. Updated March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.